Loading clinical trials...
Loading clinical trials...
A Phase I Study to Assess the Safety and Efficacy of [225Ac]Ac-DOTATATE in Patients With Inoperable, Locally Advanced or Metastatic, Progressive, Well-Differentiated,SSTR+ GEP-Nens
Conditions
Interventions
[225Ac]Ac-DOTATATE
Locations
1
China
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China
Start Date
September 29, 2024
Primary Completion Date
December 31, 2025
Completion Date
March 31, 2026
Last Updated
June 26, 2025
NCT03206060
NCT06202066
NCT07129252
NCT07404176
NCT05963867
NCT04464122
Lead Sponsor
Peking University Cancer Hospital & Institute
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions